DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 2,008 filers reported holding DANAHER CORPORATION in Q1 2022. The put-call ratio across all filers is 1.38 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $8,183,579 | -14.1% | 32,985 | -16.9% | 2.71% | -1.2% |
| Q2 2023 | $9,523,200 | -6.3% | 39,680 | -1.6% | 2.75% | -8.1% |
| Q1 2023 | $10,158,473 | -3.7% | 40,305 | +1.4% | 2.99% | -6.5% |
| Q4 2022 | $10,552,303 | +11.3% | 39,757 | +8.3% | 3.20% | -0.5% |
| Q3 2022 | $9,478,000 | +0.5% | 36,694 | -1.4% | 3.22% | +5.3% |
| Q2 2022 | $9,432,000 | -11.5% | 37,204 | +2.4% | 3.05% | +5.0% |
| Q1 2022 | $10,659,000 | -7.6% | 36,339 | +3.6% | 2.91% | -3.0% |
| Q4 2021 | $11,537,000 | +8.7% | 35,064 | +0.6% | 3.00% | -1.3% |
| Q3 2021 | $10,615,000 | +7.1% | 34,869 | -5.6% | 3.04% | +7.7% |
| Q2 2021 | $9,915,000 | +9.2% | 36,949 | -8.4% | 2.82% | +8.6% |
| Q1 2021 | $9,077,000 | -6.9% | 40,328 | -8.1% | 2.60% | -12.6% |
| Q4 2020 | $9,753,000 | -0.1% | 43,903 | -3.2% | 2.97% | -14.8% |
| Q3 2020 | $9,766,000 | +11.9% | 45,355 | -8.1% | 3.48% | +3.8% |
| Q2 2020 | $8,730,000 | +18.5% | 49,370 | -7.2% | 3.36% | -1.1% |
| Q1 2020 | $7,365,000 | -9.6% | 53,210 | +0.3% | 3.40% | +11.6% |
| Q4 2019 | $8,143,000 | +9.4% | 53,060 | +3.0% | 3.04% | -0.3% |
| Q3 2019 | $7,442,000 | -1.0% | 51,526 | -2.0% | 3.05% | -1.7% |
| Q2 2019 | $7,516,000 | +9.3% | 52,591 | +1.0% | 3.11% | +5.1% |
| Q1 2019 | $6,874,000 | +28.1% | 52,071 | +0.1% | 2.96% | +14.3% |
| Q4 2018 | $5,365,000 | -4.0% | 52,027 | +1.2% | 2.59% | +6.2% |
| Q3 2018 | $5,586,000 | +18.0% | 51,417 | +7.2% | 2.43% | +7.3% |
| Q2 2018 | $4,734,000 | +0.1% | 47,972 | -0.7% | 2.27% | -5.7% |
| Q1 2018 | $4,730,000 | +8.4% | 48,312 | +2.7% | 2.40% | +12.4% |
| Q4 2017 | $4,365,000 | +8.2% | 47,032 | -0.0% | 2.14% | +2.1% |
| Q3 2017 | $4,035,000 | +5.9% | 47,042 | +4.2% | 2.09% | -0.8% |
| Q2 2017 | $3,809,000 | -1.4% | 45,132 | -0.1% | 2.11% | -4.0% |
| Q1 2017 | $3,863,000 | +7.4% | 45,162 | -2.2% | 2.20% | +3.8% |
| Q4 2016 | $3,596,000 | -0.8% | 46,198 | -0.1% | 2.12% | -4.3% |
| Q3 2016 | $3,625,000 | -22.4% | 46,243 | 0.0% | 2.21% | -21.9% |
| Q2 2016 | $4,670,000 | +6.4% | 46,243 | -0.0% | 2.83% | +2.5% |
| Q1 2016 | $4,388,000 | +2.7% | 46,258 | +0.6% | 2.77% | -0.3% |
| Q4 2015 | $4,271,000 | +9.2% | 45,978 | +0.2% | 2.77% | +2.9% |
| Q3 2015 | $3,911,000 | +0.2% | 45,893 | +0.7% | 2.70% | +6.9% |
| Q2 2015 | $3,902,000 | +1.3% | 45,593 | +0.5% | 2.52% | +1.2% |
| Q1 2015 | $3,853,000 | -0.2% | 45,383 | +0.7% | 2.49% | -1.8% |
| Q4 2014 | $3,862,000 | +12.6% | 45,063 | -0.2% | 2.54% | +7.2% |
| Q3 2014 | $3,430,000 | -3.7% | 45,148 | -0.2% | 2.36% | -3.7% |
| Q2 2014 | $3,563,000 | +3.8% | 45,248 | -1.1% | 2.45% | +0.8% |
| Q1 2014 | $3,431,000 | -5.6% | 45,748 | -2.9% | 2.43% | -5.5% |
| Q4 2013 | $3,636,000 | +7.3% | 47,100 | -3.6% | 2.58% | -1.0% |
| Q3 2013 | $3,389,000 | +9.0% | 48,880 | -0.5% | 2.60% | +7.9% |
| Q2 2013 | $3,110,000 | – | 49,140 | – | 2.41% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |